Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Payables (2016 - 2026)

Cartesian Therapeutics has reported Payables over the past 12 years, most recently at $1.6 million for Q1 2026.

  • Quarterly Payables fell 23.8% to $1.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Mar 2026, down 23.8% year-over-year, with the annual reading at $1.3 million for FY2025, 347.22% up from the prior year.
  • Payables was $1.6 million for Q1 2026 at Cartesian Therapeutics, up from $1.3 million in the prior quarter.
  • Over five years, Payables peaked at $3.2 million in Q4 2023 and troughed at $214000.0 in Q3 2022.
  • The 5-year median for Payables is $693000.0 (2022), against an average of $1.2 million.
  • The largest YoY upside for Payables was 971.91% in 2024 against a maximum downside of 90.86% in 2024.
  • A 5-year view of Payables shows it stood at $316000.0 in 2022, then soared by 896.84% to $3.2 million in 2023, then crashed by 90.86% to $288000.0 in 2024, then soared by 347.22% to $1.3 million in 2025, then grew by 24.07% to $1.6 million in 2026.
  • Per Business Quant, the three most recent readings for RNAC's Payables are $1.6 million (Q1 2026), $1.3 million (Q4 2025), and $2.2 million (Q3 2025).